Voiding Dysfunction in a Man with Parkinsonism and Elevated Post-Void Residual

Dual pathology is likely. Parkinson's disease commonly causes detrusor overactivity (urgency, frequency, urge incontinence) due to loss of dopaminergic inhibition of the micturition reflex. However, an elevated PVR of 220 mL and a history of retention indicate bladder outlet obstruction and/or detrusor underactivity as well.

Diagnostic approach:

• History: Differentiate storage vs voiding symptoms; quantify fluid intake, caffeine, and medications (anticholinergics, alpha-blockers). Assess falls - could be related to urgency or to parkinsonism.
• Examination: Prostate size on DRE, neurologic exam for sacral function (bulbocavernosus reflex, anal tone, perineal sensation), and assessment of parkinsonism severity.
• Urinalysis and culture - exclude infection.
• PVR - already 220 mL; repeat to confirm.
• Urodynamics - the key test in this setting. It distinguishes:
  • Detrusor overactivity with or without detrusor sphincter dyssynergia (unlikely in Parkinson's but possible in MSA)
  • Bladder outlet obstruction (high pressure, low flow)
  • Detrusor underactivity (low pressure, poor contractility) - important because treating with alpha-blockers or surgery would be inappropriate if the bladder does not contract.
• Consider MSA if there is autonomic failure, orthostatic hypotension, or atypical parkinsonism - MSA often causes detrusor underactivity and sphincter dysfunction.

Interpretation of urgency + elevated PVR: Suggests detrusor overactivity with impaired emptying - either BOO causing secondary overactivity, or a combination of Parkinson's overactivity and underactive detrusor. This matters because anticholinergics could worsen retention.

Risks of anticholinergics in this patient:

• Worsening retention - with a PVR of 220 mL and a history of retention, anticholinergics can precipitate complete retention. Use with caution and monitor PVR.
• Cognitive effects - anticholinergics (especially oxybutynin) can worsen cognition and precipitate delirium, particularly in Parkinson's and the elderly. Prefer trospium (does not cross the blood-brain barrier) or a beta-3 agonist (mirabegron).
• Fall risk - anticholinergics contribute to falls via sedation, confusion, and orthostasis.
• Constipation - already common in Parkinson's.

Alternatives and sequencing:

1. Optimize alpha-blocker - he is on tamsulosin; ensure he is on the maximum dose and assess response. Alpha-blockers may improve emptying.
2. Beta-3 agonist (mirabegron) - avoids anticholinergic burden; monitor BP (can raise it) and PVR.
3. If anticholinergic needed, use trospium (quaternary amine, minimal CNS penetration) and monitor PVR.
4. Behavioral therapy - timed voiding, bladder training, fluid/caffeine modification, and pelvic floor exercises.
5. Treat constipation - it worsens urgency and retention.
6. If PVR rises or retention recurs - consider clean intermittent catheterization; this may be preferable to escalating anticholinergics.
7. Surgical options - if urodynamics show BOO with a contractile detrusor, TURP may help; if detrusor underactivity dominates, surgery is unlikely to help and may worsen incontinence.

Key trap: Starting an anticholinergic without checking PVR in a patient with known retention risk. Also, forgetting that oxybutynin worsens cognition in the elderly.

Findings: Detrusor overactivity + contractile detrusor + BOO. This is a mixed picture - the overactivity may be secondary to obstruction, and relieving obstruction may improve both storage and voiding symptoms.

Options:

1. Continue/optimize medical therapy - alpha-blocker (already on tamsulosin) plus a beta-3 agonist or trospium for overactivity. Reasonable if symptoms are tolerable and PVR is stable. But he has had retention and a rising creatinine, which argues for intervention.
2. TURP (or laser enucleation) - relieves BOO. In a contractile detrusor with BOO, TURP can improve flow and reduce PVR; overactivity often improves after decompression. Risks: incontinence (especially if sphincter weakness), retrograde ejaculation (irrelevant if not fertility-desiring), bleeding, and the need for anesthesia in a Parkinson's patient (drug interactions - avoid metoclopramide and some antiemetics; beware of dopamine antagonists).
3. Intermittent catheterization - if detrusor underactivity dominates or surgery is high-risk.

Counseling:

• Surgery can help if BOO is the dominant driver; but if the detrusor is truly underactive, TURP may not restore emptying and could worsen incontinence.
• Parkinson's-specific risks: anesthesia sensitivity, postoperative delirium, and drug interactions (avoid dopamine antagonists like metoclopramide, haloperidol; use ondansetron cautiously).
• Falls: improving urgency may reduce falls; but surgery carries its own risks.
• Shared decision: Given two falls, a retention episode, and rising creatinine, I would favor intervention - either TURP if he is fit, or intermittent catheterization plus medical therapy if not.
• Follow-up: Reassess PVR and symptoms after intervention; repeat urodynamics if unclear.

Key trap: Assuming all overactivity is idiopathic and treating with anticholinergics alone, when BOO is the driver. Also, ignoring the anesthetic and drug-interaction risks of Parkinson's.